KRAS and neoplasm: Using mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) mouse models, we show that loss of TIGAR delays the emergence of premalignant pancreatic intraepithelial neoplasia (PanIN) lesions, but enhances the metastatic capacity of the tumor cells, leading to decreased survival.